Single-dose intraperitoneal administration of AChE inhibitor RIVA dose-dependently reduced the total number and the mean duration of SWDs in WAG/Rij rats. Interestingly, long-term RIVA administration to the WAG/Rij rats increased the number of SWDs and decreased the mean duration of SWDs. Furthermore, long-term RIVA administration decreased learning-memory abilities and anxiety-like behavior in WAG/Rij rats, while RIVA only decreased anxiety-like behavior in Wistar rats. In addition, long-term administration of RIVA caused a decrease in TRPV1 gene expression in epileptic WAG/Rij rats while it caused an increase in in non-epileptic Wistar rats.
The cholinergic system has an essential role in many physiological functions in the brain such as neuronal excitability, synaptic transmission, and synaptic plasticity [35]. In terms of epileptic seizures, the effect of the cholinergic system seems to be double-sided. While the selective activation of cholinergic neurons could produce significant anti-seizure effects [12], the systemic administration of cholinergic agonists carbachol or pilocarpine has long been reported to trigger seizure activity [13]. On the other hand, acetylcholinesterase inhibitor drugs contain conflicting results on epileptic seizures. Seizure resistance was increased by an AChE inhibitor donepezil in Scn1a mutant mice and wild-type littermates by the activation of GABAA receptors [36]. Additionally, Huperzine A, a blood-brain barrier permeable selective reversible inhibitor of AChE, has shown a protective effect against NMDA-induced seizures and status epilepticus [37]. Contrary to these studies, tacrine, another AChE inhibitor, increased the seizure severity and facilitated the formation of PTZ kindling in mice [38].
Only a limited number of studies have examined the relationship between the cholinergic system and the absence seizures. Unilateral cholinotoxine injections to the reticular thalamic nucleus decreased the number and duration of SWDs compared to the basal recordings [39]. Danober et al. reported that acute systemic injections of muscarinic receptor agonists oxotremorine or pilocarpine, and an acetylcholinesterase inhibitor physostigmine reduced the duration of SWDs in a dose-dependent manner in GAERS rat. Interestingly, the muscarinic receptor antagonist scopolamine increased the duration of SWDs at lower doses, while it suppressed SWDs at higher doses [20]. In the present study, single-dose administration of RIVA dose-dependently decreased the mean duration of SWDs, as physostigmine mentioned above. Also, RIVA decreased the number of SWDs different from Danober et al. [20]. However, there is no data regarding long-term AChE inhibition in the absence epilepsy. In contrast to the acute effect, long-term high-dose RIVA administration increased the total number of SWDs and decreased the mean duration of SWDs. Moreover, long-term low-dose RIVA administration increased the number of SWDs compared to single-dose administration and similar to the baseline activity without affecting the mean duration. T-type calcium channels [4] and HCN channels [40, 41] are involved in the pathogenesis of absence seizures, which interact with the acetylcholine pathway. This may explain the effect of RIVA on the absence epileptic activity in the present study. The low threshold T-type Ca2+ conductance of the cat thalamic lateral geniculate nucleus (LGN) relay cells was directly inhibited by ACh when the membrane potential was clamped to the control level and this inhibitory effect was independent of the changes in membrane potential by ACh [42]. Moreover, in another patch-clamp study, Hildebrandt et al. have noted that activation of M1 muscarinic acetylcholine receptors selectively and reversibly inhibits Cav3.3 channel activity but either no effect on Cav3.1 and Cav3.2 peak current amplitudes and this modulation was observed for both rat and human T-type Ca2+ channel variants [43]. On the other hand, neostigmine-stimulated endogenous acetylcholine release showed a selective suppressive effect on Ih and resonance in burst firing in Wistar rats [44]. Furthermore, in the cholinergic interneurons of the striatum, activation of muscarinic receptors downregulates internal cAMP which would result in the reduction of Ih and inhibition of spontaneous firing [45]. In light of the aforementioned studies, since the increase in acetylcholine can suppress both T-type Ca2+ channels and HCN channels, single-dose RIVA administration may reduce SWDs parameters by this way. Moreover, long-term RIVA administration may alter the expression of these channels, which may lead to an increase in SWDs, just as the suppression of HCN channels caused an increase in HCN channel expression in our previous study [41].
Learning-memory abilities difficulties and anxiety disorders may frequently occur in individuals with absence epilepsy [46]. In many studies, genetic absence epileptic WAG/Rij rats exhibited memory and learning problems [47], depression-like symptoms [47], and anxiety-related symptoms [48]. Anticholinergic agent RIVA, which has not been studied in epilepsy, is used to slow down the bad progression of learning-memory abilities and anxiety, which are symptoms of dementia [49–51]. In the present study, long-term (21 days) high-dose of RIVA were administered to both 8-month-old WAG/Rij rats and non-epileptic age-matched Wistar rats. WAG/Rij rats showed a reduction in the total number of arm and new arm entries compared to the Wistar rats. On the other hand, long-term RIVA administration did not affect the learning-memory abilities performance in Wistar rats. However, almost all observed Y-maze parameters were reduced in WAG/Rij rats with the long-term administration of RIVA, which increased SWDs. These findings are in line with Leo et al. (2019)who suggested that learning-memory abilities performance is likely linked to an increase in spike-wave discharges [9]. Regarding anxiety, as in many studies [48, 52], WAG/Rij rats had a higher anxiety-like behavior than Wistar rats in the present study. Also, Fedosova et al. noted that WAG/Rij rats display increased anxiety and higher stress response after 2-month-old compared to the Wistar rats [10]. Moreover, long-term RIVA administration decreased anxiety-like behavior both in WAG/Rij and Wistar rats. On the other hand, several studies have shown that too high or too low anxiety responses can have negative consequences for both vital responses and some abilities such as learning-memory abilities [53]. Very low or very high levels of stress lead to learning-memory abilities impairment which is called an “inverted U relationship” [53, 54]. In consequence, the increased number of SWDs and low anxiety-like behavior with long-term RIVA administration are likely to cause learning-memory abilities impairment.
TRPV1, a calcium-permeable cation channel [55], is well-studied in the peripheral nervous system, however, its role in the central nervous system remains to be investigated in detail [56, 57]. TRPV1 is also associated with a wide range of functions in the central nervous system, such as fear, anxiety, stress, learning-memory abilities, thermoregulation, pain, and synaptic plasticity [58–60]. Moreover, it can also be associated with neurological diseases such as epilepsy [61–63]. Conflicting results have been reported for TRPV1 in convulsive epilepsy. Since TRPV1 channels increase calcium ion accumulation, stimulation of these channels is expected to increase tonic-clonic seizures under normal conditions. However, studies reveal different results. Manna and Umathe (2012) found that intracerebroventricular injection of TRPV1 agonist capsaicin exhibited proconvulsant activity that was blocked by capsazepine pretreatment in PTZ-induced seizures in mice. Conversely, intraperitoneal administration of capsaicin decreased seizure severity and neuronal damage in PTZ-induced seizures in rats [63]. Furthermore, other TRPV1 agonist piperine delayed the onset of myoclonic jerks and generalized clonic seizures and decreased the seizure stage and mortality in PTZ-induced seizures in mice [62]. Interestingly, Jia et al. showed that hippocampal administration of both TRPV1 agonists or antagonists reduced the susceptibility to PTZ-induced seizures in mice. Moreover, in the same study, TRPV1 knockout mice and hippocampal TRPV1 overexpression mice showed decreased susceptibility to PTZ-induced seizures [24].
Increased TRPV1 expression was reported in the temporal cortex and hippocampus of patients with mesial temporal lobe epilepsy [64]. Moreover, expression levels of TRPV1 mRNA and protein increased after febrile seizures in wild-type mice [65]. In the status epilepticus model induced by pilocarpine, an acetylcholine agonist acting on muscarinic receptors, the TRPV1 receptor was overexpressed in the dentate gyrus of mice [66] and the hippocampus of the rats [67]. Regarding the absence epilepsy, only one study indicated the levels of TRPV1 [25]. According to the immunoblotting analysis, protein levels of TRPV1 were lower in two- and 6-month-old WAG/Rij rats compared to age-matched Wistar rats in the somatosensory cortex [68]. Interestingly, TRPV1 protein expression was lower in the 2-month-old and higher in the 6-month-old WAG/Rij rats compared to age-matched Wistar rats in the hippocampus [68]. In contrast to this study, there was no difference in TRPV1 gene expression in both the somatosensory cortex and hippocampus of 8-month-old WAG/Rij compared to age-matched Wistar rats. The protein levels did not measured in experimental groups which may be considered the major limitation of the present study. On the other hand, long-term RIVA administration decreased the mRNA levels of TRPV1 in WAG/Rij rats in the somatosensory cortex and hippocampus, whereas mRNA levels of TRPV1 were increased in Wistar rats after long-term RIVA administration in both regions. We consider that these different effects may be explained due to genetic defects such as channelopathies in WAG/Rij rats [41, 69]. Although the role of activation or inhibition of TRPV1 receptors on SWDs is not known yet, Talebi et al. suggested that reduction of the TRPV1 receptors could play an important role in the pathophysiology of absence epilepsy [68]. Therefore, we suggest that decreased TRPV1 channel expression may lead to increased absence seizures, however further studies are needed to prove this hypothesis.
In conclusion, while single-dose administration of AChE inhibitor RIVA decreased the SWDs parameters, long-term administration caused an increase in the number of SWDs in WAG/Rij rats. This effect may be mediated through altered expressions of calcium channels such as T-type, HCN, and TRPV1 channels. Long-term RIVA treatment decreased learning-memory abilities and anxiety in WAG/Rij rats, but only anxiety in Wistar rats. TRPV1 gene expression was found to be decreased in WAG/Rij rats, however, it increased in Wistar rats suggesting this may be due to the genetic deficiencies of WAG/Rij rats.